“With the compelling preclinical data we presented at the International Congress of Parkinson’s Disease and Movement Disorders and the initiation of our Phase 1 clinical trial of GT-02287, we have made tremendous progress this past quarter,” said Matthias Alder, Chief Executive Officer of Gain Therapeutics. “Dose escalation continues as planned, and we look forward to providing updates on the study in the first half of next year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GANX:
- Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
- GANX Earnings this Week: How Will it Perform?
- Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Gain announces dosing of first two subjects in Phase 1 trial of GT-02287
- Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
